Top

Published in:

01-12-2015 | RADIOTHERAPY

Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales

Authors: Giuseppe Ferrera, Gianluca Mortellaro, Mariella Mannino, Giovanni Caminiti, Antonio Spera, Vanessa Figlia, Giuseppina Iacoviello, Gioacchino Di Paola, Rosario Mazzola, Antonio Lo Casto, Filippo Alongi, Maria Pia Pappalardo, Roberto Lagalla

Published in: La radiologia medica | Issue 12/2015

Abstract

Introduction

Based on radiobiology evidence, hypofractionated radiotherapy has the potential of improving treatment outcome in prostate cancer patients. In this study, we evaluated the safety, in terms of acutetoxicity, of using moderate hypofractionated radiotherapy delivered with Helical Tomotherapy (HT) to treat prostate cancer patients.

Materials and methods

Between December 2012 and April 2014, 42 consecutive patients were treated with hypofractionated radiotherapy using HT. All patients received 70 Gy in 28 fractions to PTV1, which included the prostate. In the intermediate risk group, 61.6 Gy were delivered to PTV2, which included the seminal vesicles. In high risk patients, the pelvic nodes were added (PTV3) and received 50.4 Gy. Acute toxicity was recorded prospectively with RTOG and Common Terminology Criteria for Adverse Events 3.0, retrospectively with CTCAE 4.0. Expanded Prostate Cancer Index Composite (EPIC) was measured at baseline and 3 months after end of treatment, to investigate health related quality of life with regards to bladder and gastrointestinal function.

Results

Acute toxicity was acceptable, independently from the system used to score side effects. Moderate genitourinary toxicity was more frequent than gastrointestinal toxicity. No correlation between acute side effects and patients’ characteristics or physical dose parameters was registered. EPIC evaluation showed a negligible difference in urinary and bowel function post-treatment, that did not reach statistical significance.

Conclusions

Our experience confirms the safety of moderate hypofractionation delivered with HT in prostate cancer patients with low, intermediate and high risk.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 CrossRefPubMed

Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105CrossRefPubMed

Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233CrossRefPubMed

Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116CrossRefPubMed

Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, Di Muzio N (2009) IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93(2):207–212. doi:10.1016/j.radonc.2009.08.042 CrossRefPubMed

Fiorino C, Alongi F, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, Valdagni R, Fazio F, Calandrino R (2008) Physics aspects of prostate tomotherapy: planning optimization and image-guidance issues. Acta Oncol 47(7):1309–1316CrossRefPubMed

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84(1):125–129CrossRefPubMed

Proust-Lima C, Taylor JM, Sécher S, Sandler H, Kestin L, Pickles T, Bae K, Allison R, Williams S (2011) Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79(1):195–201. doi:10.1016/j.ijrobp.2009.10.008 PubMedCentralCrossRefPubMed

Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9 − 2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24CrossRefPubMed

10.

Leborgne F, Fowler J, Leborgne JH, Mezzera J (2012) Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 82(3):1200–1207CrossRefPubMed

11.

Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78(1):11–18. doi:10.1016/j.ijrobp.2009.07.169112 CrossRefPubMed

12.

Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, De Neve W, Storme G (2006) Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 80(1):78–81CrossRefPubMed

13.

Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, Valdagni R, Calandrino R, Fazio F (2009) Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74(2):392–398. doi:10.1016/j.ijrobp.2008.08.038 CrossRefPubMed

14.

Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23(25):6132–6138CrossRefPubMed

15.

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64(2):518–526PubMedCentralCrossRefPubMed

16.

Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43–54. doi:10.1016/S1470-2045(11)70293-5 CrossRefPubMed

17.

Katz AJ, Kang J (2014) Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 28(4):301. doi:10.3389/fonc.2014.00301

18.

Arcangeli S, Scorsetti M, Alongi F (2012) Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 84(1):101–108. doi:10.1016/j.critrevonc.2011.11.009 CrossRefPubMed

19.

NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines^®) prostate cancer2014version4. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#prostate

20.

ICRU Report 83. 3 (2010) Special considerations regarding absorbed-dose and dose–volume prescribing and reporting in IMRT. J ICRU 10:14

21.

ICRU Report 62 (1999) Prescribing, recording and reporting photon beam therapy. Bethesda (MD): International Commission on Radiation Units and Measurements

22.

Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68(5):1424–1430CrossRefPubMed

23.

Kotecha R, Marwaha G, Hearn JW, Weller MA, Kupelian P, Reddy CA, Ciezki JP, Stephans K, Tendulkar RD (2014) A comparison of long-term treatment-related toxicities between moderately hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 90(1, Supplement):S423–S424CrossRef

24.

Acute Radiation Morbidity Scoring Criteria RTOG. http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx

25.

Common Terminology Criteria for Adverse Events,Version 3.0: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf

26.

Common Terminology Criteria for Adverse Events,Version 4.0 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

27.

Sanda MG, Rl Dunn, Michalski J et al (2008) Qaulity of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261CrossRefPubMed

28.

Lopez Guerra JL, Isa N, Matute R, Russo M, Puebla F, Kim MM, Sanchez-Reyes A, Beltran C, Jaen J, Bourgier C, Marsiglia H (2013) Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer. Clin Transl Oncol 15(4):271–277. doi:10.1007/s12094-012-0907-y CrossRefPubMed

29.

Keiler L, Dobbins D, Kulasekere R, Einstein D (2007) Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol 84(2):171–176CrossRefPubMed

30.

Kong M, Hong SE, Chang SG (2014) Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity. Onco Target Ther 7:553–566. doi:10.2147/OTT.S61465 CrossRef

31.

Nakamura N, Shikama N, Takahashi O, Ito M, Hashimoto M, Uematsu M, Hama Y, Sekiguchi K, Nakagawa K (2010) Variability in bladder volumes of full bladders in definitive radiotherapy for cases of localized prostate cancer. Strahlenther Onkol 186(11):637–642. doi:10.1007/s00066-010-2105-6 CrossRefPubMed

32.

O’Doherty UM, McNair HA, Norman AR, Miles E, Hooper S, Davies M, Lincoln N, Balyckyi J, Childs P, Dearnaley DP, Huddart RA (2006) Variability of bladder filling in patients receiving radical radiotherapy to the prostate. Radiother Oncol 79(3):335–340CrossRefPubMed

33.

Stam MR, van Lin EN, van der Vight LP, Kaanders JH, Visser AG (2006) Bladder filling variation during radiation treatment of prostate cancer: can the use of a bladder ultrasound scanner and biofeedback optimize bladder filling? Int J Radiat Oncol Biol Phys 65(2):371–377CrossRefPubMed

34.

Hynds S, McGarry CK, Mitchell DM, Early S, Shum L, Stewart DP, Harney JA, Cardwell CR, O’Sullivan JM (2011) Assessing the daily consistency of bladder filling using an ultrasonic Bladderscan device in men receiving radical conformal radiotherapy for prostate cancer. Br J Radiol 84(1005):813–818. doi:10.1259/bjr/50048151 PubMedCentralCrossRefPubMed

35.

King BL, Butler WM, Merrick GS, Kurko BS, Reed JL, Murray BC, Wallner KE (2011) Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 79(5):1350–1357. doi:10.1016/j.ijrobp.2009.12.053 CrossRefPubMed

36.

Engels B, Soete G, Gevaert T, Storme G, Michielsen D, De Ridder M (2014) Impact of planning target volume margins and rectal distention on biochemical failure in image-guided radiotherapy of prostate cancer. Radiother Oncol 111(1):106–109. doi:10.1016/j.radonc.2014.02.009 CrossRefPubMed

37.

Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, Montorsi F, Rigatti P, Calandrino R, Fazio F (2007) Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients withlocalized prostate cancer. Radiother Oncol 84(2):164–170CrossRefPubMed

38.

Barra S, Vagge S, Marcenaro M, Blandino G, Timon G, Vidano G, Agnese D, Gusinu M, Cavagnetto F, Corvò R (2014) Image guided hypofractionated radiotherapy by helical tomotherapy for prostate carcinoma: toxicity and impact on Nadir PSA. Biomed Res Int 2014:541847. doi:10.1155/2014/541847 PubMedCentralCrossRefPubMed

39.

Alongi F, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F, Reggiori G, Clivio A, Cozzi L, Scorsetti M (2012) Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 188(11):990–996. doi:10.1007/s00066-012-0171-7 CrossRefPubMed

40.

Geier M, Astner ST, Duma MN, Jacob V, Nieder C, Putzhammer J, Winkler C, Molls M, Geinitz H (2012) Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol 188(5):410–416. doi:10.1007/s00066-012-0081-8 CrossRefPubMed

41.

Jereczek-Fossa BA, Santoro L, Zerini D, Fodor C, Vischioni B, Dispinzieri M, Bossi-Zanetti I, Gherardi F, Bonora M, Caputo M, Vavassori A, Cambria R, Garibaldi C, Cattani F, Matei DV, Musi G, De Cobelli O, Orecchia R (2013) Image-guided hypofractionated radiotherapy and quality of life in localized prostate cancer: prospective longitudinal study on 337 patients. J Urol

42.

Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Menard C, Milosevic M, Warde P, Catton C (2007) Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 69:1084–1089CrossRefPubMed

Title: Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales
Authors: Giuseppe Ferrera
Gianluca Mortellaro
Mariella Mannino
Giovanni Caminiti
Antonio Spera
Vanessa Figlia
Giuseppina Iacoviello
Gioacchino Di Paola
Rosario Mazzola
Antonio Lo Casto
Filippo Alongi
Maria Pia Pappalardo
Roberto Lagalla
Publication date: 01-12-2015
Publisher: Springer Milan
Published in: La radiologia medica / Issue 12/2015
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-015-0555-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales

Abstract

Introduction

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2015

Implementation, reliability, and feasibility test of an Open-Source PACS

2015 Scientific Referees

Combined thrombus aspiration and recanalization in treating Budd–Chiari syndrome with inferior vena cava thrombosis

Effectiveness of chemotherapy and radiotherapy for laryngeal preservation in advanced laryngeal cancer: a meta-analysis and systematic review

The treatment of patients with 1–3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis

Reliability of frontal sinus by cone beam-computed tomography (CBCT) for individual identification